histamine has been researched along with Influenza, Human in 19 studies
Influenza, Human: An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The mean duration of fever in the Ergoferon and oseltamivir groups was 2." | 5.22 | Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. ( Andrianova, E; Averyanov, A; Bart, B; Epstein, O; Minina, E; Putilovskiy, M; Rafalsky, V, 2016) |
| "The pediatric dosage form of Egroferon--a drug indicated for the treatment of influenza and acute respiratory infections (ARIs)--is developed taking in account the broad range of pathogens (most of which are viruses), and age-dependent features of immune system reactions (absence of specific immunity and immunological memory, relative "immaturity" of immune reactions, reduced interferon production by immunocompetent cells, etc." | 2.79 | [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial]. ( Bal'tserovich, NB; Galustian, AN; Geppe, NA; Kamaev, AV; Kondiurina, EG; Laléko, SL; Lazareva, SG; Mel'nikova, IM; Pak, TE; Perminova, OA; Sabitov, AU; Zhiglinskaia, OV, 2014) |
| "Influenza was confirmed in 52 patients by QuickVue rapid diagnosis." | 2.77 | [Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial]. ( Andrianova, EN; Aver'ianov, AV; Babkin, AP; Bart, BIa; Epshteĭn, OI; Kostinov, MP; Kozyrev, OA; Minina, ES; Nechaev, VB; Petrov, DV; Putilovskiĭ, MA; Sel'kova, EP; Volchetskiĭ, AL, 2012) |
| "Six subjects received live, attenuated influenza virus by nasal drops and by aerosol." | 2.67 | Bronchial hyperresponsiveness in normal subjects during attenuated influenza virus infection. ( Elkin, RB; Empey, DW; Jacobs, L; Laitinen, LA; Mills, J; Nadel, JA, 1991) |
| "Importantly, human H1N1, H3N2, and influenza B virus isolates also could activate mast cells in vitro." | 1.39 | Inflammatory response of mast cells during influenza A virus infection is mediated by active infection and RIG-I signaling. ( Graham, AC; Hilmer, KM; Obar, JJ; Zickovich, JM, 2013) |
| "The ability to prevent or treat viral respiratory tract infections is currently limited." | 1.31 | Virus-induced asthma attacks. ( Jacoby, DB, 2002) |
| "Twenty-one subjects were infected with influenza-A virus and had significant increases in daily secretion weights and symptom scores extending from day 2 to 7, post-inoculation." | 1.29 | Pattern of nasal secretions during experimental influenza virus infection. ( Doyle, WJ; Fireman, P; Hayden, F; Kaliner, MA; Kaplan, AP; Shibayama, Y; Skoner, DP; White, M, 1996) |
| "Live attenuated influenza A virus (R." | 1.26 | Bronchial reactivity following uncomplicated influenza A infection in healthy subjects and in asthmatic patients. ( Kava, T; Laitinen, LA, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (52.63) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Graham, AC | 1 |
| Hilmer, KM | 1 |
| Zickovich, JM | 1 |
| Obar, JJ | 1 |
| Geppe, NA | 1 |
| Kondiurina, EG | 1 |
| Galustian, AN | 1 |
| Pak, TE | 1 |
| Bal'tserovich, NB | 1 |
| Zhiglinskaia, OV | 1 |
| Kamaev, AV | 1 |
| Lazareva, SG | 1 |
| Laléko, SL | 1 |
| Mel'nikova, IM | 1 |
| Perminova, OA | 1 |
| Sabitov, AU | 1 |
| Rafalsky, V | 1 |
| Averyanov, A | 1 |
| Bart, B | 1 |
| Minina, E | 1 |
| Putilovskiy, M | 1 |
| Andrianova, E | 1 |
| Epstein, O | 1 |
| Aver'ianov, AV | 1 |
| Babkin, AP | 1 |
| Bart, BIa | 1 |
| Volchetskiĭ, AL | 1 |
| Minina, ES | 1 |
| Kozyrev, OA | 1 |
| Kostinov, MP | 1 |
| Petrov, DV | 1 |
| Sel'kova, EP | 1 |
| Putilovskiĭ, MA | 1 |
| Nechaev, VB | 1 |
| Epshteĭn, OI | 1 |
| Andrianova, EN | 1 |
| BRONITKI, A | 3 |
| DEREVICI, A | 3 |
| BALMUS, G | 3 |
| Curry, JJ | 1 |
| Götz, M | 1 |
| Walters, EH | 1 |
| Laitinen, LA | 2 |
| Kava, T | 1 |
| Doyle, WJ | 3 |
| Skoner, DP | 3 |
| White, M | 1 |
| Hayden, F | 1 |
| Kaplan, AP | 1 |
| Kaliner, MA | 1 |
| Shibayama, Y | 1 |
| Fireman, P | 3 |
| Gentile, DA | 2 |
| Cordoro, K | 1 |
| Jacoby, DB | 1 |
| Busse, W | 1 |
| Reed, CE | 1 |
| Elkin, RB | 1 |
| Empey, DW | 1 |
| Jacobs, L | 1 |
| Mills, J | 1 |
| Nadel, JA | 1 |
| Kudashchov, NI | 1 |
| Kuliabko, OM | 1 |
| Merkel, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicentre Open Label Comparative Parallel-group Randomized Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza[NCT01804946] | Phase 4 | 161 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pneumonia, sinusitis, otitis media are examples of the influenza complications (NCT01804946)
Timeframe: Day 1 to Day 7
| Intervention | Percentage of participants (Number) |
|---|---|
| Ergoferon Group | 0 |
| Oseltamivir Group | 2 |
The quality of life was assessed in influenza patients at baseline and at the end of the treatment period using the European Quality of Life Questionnaire (EQ5D) measuring the health status by five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression (each dimension is assessed by 1 to 3 point scale; the minimum score 5 points refers to the best status, 15 points refers to the worst status). (NCT01804946)
Timeframe: Day 7 vs. Day 1
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Day 1 | Day 7 | |
| Ergoferon Group | 9.5 | 5.4 |
| Oseltamivir Group | 9.4 | 5.4 |
The patient subjective health status assessment was based on Visual Analogue Scale - VAS). VAS includes a rating of current health status from 0 (worst) to 100 (best). (NCT01804946)
Timeframe: Day 7 vs. Day 1
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Day 1 | Day 7 | |
| Ergoferon Group | 41.6 | 87.7 |
| Oseltamivir Group | 46.2 | 88.0 |
The axillary temperature was assessed during a physical examination at Day 1, 3 and 7; axillary temperature was assessed in degrees (Celsius, °С) (NCT01804946)
Timeframe: on days 1, 3 and 7 of the observation
| Intervention | °C (Mean) | ||
|---|---|---|---|
| Axillary temperature, Day 1 | Axillary temperature, Day 3 | Axillary temperature, Day 7 | |
| Ergoferon Group | 38.3 | 37.0 | 36.5 |
| Oseltamivir Group | 38.3 | 37.0 | 36.6 |
Axillary temperature (morning and evening) decline to or below 37.0 ºС (without subsequent increase during ≥24 h) (NCT01804946)
Timeframe: Day 1 to Day 5
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Evening, Day 1 | Evening, Day 2 | Evening, Day 3 | Evening, Day 4 | Evening, Day 5 | |
| Ergoferon Group (EG) | 4 | 15 | 41 | 68 | 84 |
| Oseltamivir Goup (OG) | 1 | 15 | 43 | 72 | 88 |
Assessment of the proportion of subjects with no clinical symptoms of the disease (fever, common and respiratory symptoms) at Study Day 7 (Visit 3). The severity of influenza symptoms was assessed by a physician with 0 to 3 point scale, where 0 means no symptom, 1=mild symptom, 2=moderate symptom, and 3=severe symptom (NCT01804946)
Timeframe: on the day 7 of the observation
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Fever | Common symptoms | Respiratory symptoms | All symptoms | |
| Ergoferon Group | 100 | 61 | 83 | 47 |
| Oseltamivir Group | 100 | 64 | 76 | 49 |
The severity of influenza symptoms was assessed during a physical examination at Day 1, 3 and 7; common (10 symptoms) and respiratory (5 symptoms) symptom's total score was assessed with using the point scale: 0=No symptom; 1=Mild symptom; 2=Moderate symptom ; 3=Severe symptom. The Common Symptoms total score ranged from 0 (no symptoms) to 30 (severe symptoms). The Respiration Symptoms total score ranged from 0 (no symptoms) to 15 (severe symptoms) (NCT01804946)
Timeframe: on days 1, 3 and 7 of the observation
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Common symptoms, Day 1 | Common symptoms, Day 3 | Common symptoms, Day 7 | Respiratory symptoms, Day 1 | Respiratory symptoms, Day 3 | Respiratory symptoms, Day 7 | |
| Ergoferon Group | 19.0 | 9.2 | 2.3 | 6.1 | 4.3 | 1.3 |
| Oseltamivir Group | 18.6 | 7.8 | 1.9 | 5.9 | 4.0 | 1.4 |
A subject recorded the number of antipyretic intake in patient diary. (NCT01804946)
Timeframe: Day 1 to Day 5
| Intervention | Number of Doses (Mean) | ||||
|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | |
| Ergoferon Group | 0.65 | 0.40 | 0.19 | 0.01 | 0.00 |
| Oseltamivir Group | 0.72 | 0.49 | 0.15 | 0.03 | 0.01 |
"Time to resolution was considered as time to the absence of any flu symptom. Absence of symptoms was considered as axillary temperature decline to or below 37.0 ºС without subsequent rise, resolution of the common and respiratory symptoms.~The duration of a symptom was defined by physician recorded presence/absence of the symptoms during a physical examination at Day 1 to Day 7." (NCT01804946)
Timeframe: Day 1 to Day 7
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Fever | Common symptoms | Respiratory symptoms | All influenza symptoms | |
| Ergoferon Group | 2.1 | 2.6 | 2.7 | 2.6 |
| Oseltamivir Group | 2.3 | 2.4 | 2.6 | 2.5 |
1 review available for histamine and Influenza, Human
| Article | Year |
|---|---|
[Bronchial responsiveness in children with asthma--their reactions to non-specific and specific stimuli].
Topics: Acetylcholine; Adolescent; Aerosols; Airway Resistance; Asthma; Bronchial Provocation Tests; Bronchi | 1982 |
5 trials available for histamine and Influenza, Human
| Article | Year |
|---|---|
[Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Antibodies; Antipyretics; Antiviral Agents; Area | 2014 |
Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial.
Topics: Adolescent; Adult; Aged; Antibodies; Antiviral Agents; CD4 Antigens; Female; Fever; Histamine; Human | 2016 |
[Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial].
Topics: Adolescent; Adult; Antipyretics; Antiviral Agents; Body Temperature; CD4 Antigens; Female; Fever; Hi | 2012 |
Effect of inhibition of prostaglandin synthesis on induced bronchial hyperresponsiveness.
Topics: Adult; Airway Resistance; Bronchi; Bronchial Provocation Tests; Dose-Response Relationship, Drug; Hi | 1983 |
Bronchial hyperresponsiveness in normal subjects during attenuated influenza virus infection.
Topics: Adult; Aerosols; Airway Resistance; Bronchi; Bronchoconstriction; Hemagglutination Inhibition Tests; | 1991 |
13 other studies available for histamine and Influenza, Human
| Article | Year |
|---|---|
Inflammatory response of mast cells during influenza A virus infection is mediated by active infection and RIG-I signaling.
Topics: Animals; Chemokines; DEAD-box RNA Helicases; Histamine; Humans; Inflammation; Influenza A Virus, H1N | 2013 |
[Action of histamine on the tracheal cytograms of mice subjected to influenza infection].
Topics: Animals; Histamine; Humans; Influenza, Human; Mice; Trachea | 1961 |
[The allergic factor in experimental influenza infection. The role of histamine].
Topics: Anti-Allergic Agents; Chlorpromazine; Histamine; Histamine H1 Antagonists; Humans; Hypersensitivity; | 1961 |
[The allergic factor in experimental influenza infection. The role of histamine].
Topics: Anti-Allergic Agents; Histamine; Histamine H1 Antagonists; Humans; Hypersensitivity; Immune System D | 1961 |
COMPARATIVE ACTION OF ACETYL-BETA-METHYL CHOLINE AND HISTAMINE ON THE RESPIRATORY TRACT IN NORMALS, PATIENTS WITH HAY FEVER, AND SUBJECTS WITH BRONCHIAL ASTHMA.
Topics: Asthma; Choline; Histamine; Histamine Agents; Humans; Influenza, Human; Respiratory System; Rhinitis | 1947 |
Bronchial reactivity following uncomplicated influenza A infection in healthy subjects and in asthmatic patients.
Topics: Adolescent; Adult; Asthma; Bronchi; Female; Histamine; Humans; Influenza A virus; Influenza, Human; | 1980 |
Pattern of nasal secretions during experimental influenza virus infection.
Topics: Adult; Blood Proteins; Bradykinin; Capillary Permeability; Female; Histamine; Humans; Immunoglobulin | 1996 |
Urinary histamine metabolite elevations during experimental influenza infection.
Topics: Adolescent; Adult; Female; Gas Chromatography-Mass Spectrometry; Histamine; Humans; Imidazoles; Infl | 2001 |
Effect of experimental influenza A infection on systemic immune and inflammatory parameters in allergic and nonallergic adult subjects.
Topics: Adolescent; Adult; Female; Histamine; Histamine Release; Humans; Immunoglobulin E; Influenza A virus | 2001 |
Virus-induced asthma attacks.
Topics: Adult; Asthma; Bronchodilator Agents; Cholinergic Antagonists; Coronavirus Infections; Female; Gluco | 2002 |
In vitro studies on the mechanism of respiratory virus-induced asthma.
Topics: Asthma; Histamine; Humans; In Vitro Techniques; Influenza A virus; Influenza Vaccines; Influenza, Hu | 1979 |
[Changes in histamine metabolism in children with influenza].
Topics: Acute Disease; Child; Child, Preschool; Histamine; Histamine Antagonists; Histamine Release; Humans; | 1966 |
[Functional studies in acute respiratory tract diseases].
Topics: Acute Disease; Adolescent; Adult; Aerosols; Aged; Bronchiolitis, Viral; Bronchitis; Female; Histamin | 1973 |